Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2012
    Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease

    Objective/Rationale:
    Recently, genetic manipulation of human cells from various organs, e.g. skin, enabled direct generation of human nerve cells (so-called induced neurons – iNs) that potentially can...

  • Rapid Response Innovation Awards, 2012
    Trace Amines and Their Metabolites as Potential Heraldic Markers in Parkinson’s Disease

    Objective/Rationale:
    Tools for early and unambiguous diagnosis of PD are currently missing and disease symptoms are easily mistaken. On the other hand, prompt recognition of PD subjects may increase...

  • Rapid Response Innovation Awards, 2012
    Intestinal and Nasal Microbiota of Patients with Idiopathic Parkinson's disease

    Objective/Rationale:
    The cause of Parkinson’s disease is unknown and a reliable biomarker to identify Parkinson’s disease patients as early as possible is urgently needed. Nerve cells near the nose...

  • Dyskinesia Challenge, 2012
    The Role of CK2 in the Development of Levodopa-Induced Dyskinesia in Parkinson’s disease

    Promising Outcomes of Original Grant:
    In Parkinson’s disease, dopamine-producing neurons degenerate, leading to a lack of dopamine in the brain. This leads to profound changes in the cells which are...

  • Rapid Response Innovation Awards, 2012
    Reversing Pre-existing Pathologies of Dopamine Neurons in an Alpha-synuclein Model

    Objective/Rationale:             
    Alpha-synuclein has been identified to play the central role in Parkinson’s disease. Genome-wide association studies confirm alpha-synuclein as a risk factor for...

  • Therapeutics Development Initiative, 2012
    Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease

    Objective/Rationale: 
    HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.